why choose us

First received: June 30, 2022

Clinical Trial: A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Myeloproliferative Neoplasms

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

Brief Summary: The purpose of this study is to evaluate the safety of VAC85135 administered with ipilimumab for the treatment of myeloproliferative neoplasms (MPNs).

Read more